| Literature DB >> 28962947 |
Mathias Meyer1, Rozemarijn Vliegenthart2, Thomas Henzler3, Daniel Buergy4, Frank A Giordano4, Michael Kostrzewa3, Nils Rathmann3, Odd Terje Brustugun5, Lucio Crino6, Anne-Marie C Dingemans7, Michael Dusmet8, Dean Fennell9, Dominique Grunenwald10, Rudolf Maria Huber11, Marcin Moniuszko12, Francoise Mornex13, Mauro Papotti14, Lothar Pilz15, Suresh Senan16, Kostas Syrigos17, Maurice Pérol18, Jhanelle E Gray19, Christoph Schabel20, Jan P van Meerbeeck21, Nico van Zandwijk22, Cai Cun Zhou23, Christian Manegold24, Wieland Voigt25, Eric Dominic Roessner24.
Abstract
Although the effectiveness of screening for lung cancer remains controversial, it is a fact that most lung cancers are diagnosed at an advanced stage outside of lung cancer screening programs. In 2013, the U.S. Preventive Services Task Force revised its lung cancer screening recommendation, now supporting lung cancer screening by low-dose computed tomography in patients at high risk. This is also endorsed by many major medical societies and advocacy group stakeholders, albeit with different eligibility criteria. In Europe, population-based lung cancer screening has so far not been recommended or implemented, as some important issues remain unresolved. Among them is the open question of how enlarging pulmonary nodules detected in lung cancer screening should be managed. This article comprises two parts: a review of the current lung cancer screening approaches and the potential therapeutic options for enlarging pulmonary nodules, followed by a meeting report including consensus statements of an interdisciplinary expert panel that discussed the potential of the different therapeutic options.Entities:
Keywords: Lung cancer screening; Pulmonary nodules; Stereotactic ablative radiotherapy; Surgery
Mesh:
Year: 2017 PMID: 28962947 DOI: 10.1016/j.jtho.2017.09.1956
Source DB: PubMed Journal: J Thorac Oncol ISSN: 1556-0864 Impact factor: 15.609